Search

Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen

It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

Streptococcus pneumoniae type 18C capsular polysaccharide diphtheria CRM197 protein conjugate antigen

It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

Sapacitabine

Paquinimod

The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. … Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease.

Tyramine

There have been reports of hypertensive crisis in patients ingesting tyramine-rich diet in conjunction with monoamine oxidase inhibitors (MAOIs). … An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects.

Ad5-nCoV

)[L12675] with an expected completion in December 2020. … [L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906

TD-2749

TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

Tegoprazan

Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fa...

Stamulumab

MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.

Patupilone

Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.